NDA 212728 · Pfizer
Nurtec Odt
Rimegepant Sulfate · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: May 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Feb 27, 2020
Approved uses
3
Original approval plus efficacy supplements
Registered trials
50
19 Phase 3, 16 recruiting
FAERS reports
13,010
2,564 serious, 116 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 4, 2026.
NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults ( 1.1 ) • preventive treatment of episodic migraine in adults ( 1.2 ) 1.1 Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults . 1.2 Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.
Mechanism: Rimegepant is a calcitonin gene-related peptide receptor antagonist.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 11, 2022 Supplement 9 · Efficacy LetterLabel
- May 27, 2021 Supplement 6 · Efficacy LabelLetter
- Feb 27, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- NURTEC ODT · RIMEGEPANT SULFATE EQ 75MG BASE · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rimegepant" as an intervention, any sponsor and status, largest first.
- Open Label Safety Study in Acute Treatment of MigrainePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03266588 · 3,019 participants · Start Aug 30, 2017 · Primary completion Jul 15, 2019
Drug: Rimegepant · For: Migraine, With or Without Aura
Sites: Birmingham, Alabama; Mobile, Alabama; Glendale, Arizona · 98 sites in all
- Randomized Study in Children and Adolescents With Migraine: Acute TreatmentPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT04649242 · 2,100 participants (planned) · Start Jan 15, 2021 · Primary completion Jan 9, 2029
Drug: Rimegepant/BHV3000; Matching placebo · For: Pediatric Migraine
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tempe, Arizona · 246 sites in all
- Trial in Adult Subjects With Acute MigrainesPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03461757 · 1,811 participants · Start Feb 27, 2018 · Primary completion Oct 8, 2018
Drug: Rimegepant; Placebo · For: Migraine, With or Without Aura
Sites: Mobile, Alabama; Tempe, Arizona; Tucson, Arizona · 69 sites in all
- Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of MigrainePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04574362 · 1,648 participants · Start Oct 22, 2020 · Primary completion Nov 24, 2021
Drug: Rimegepant; Placebo · For: Acute Migraine
Sites: Bengbu, China; Hefei, China; Lu'an, China · 90 sites in all
- Efficacy and Safety Trial of Rimegepant for Migraine Prevention in AdultsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03732638 · 1,590 participants · Start Nov 14, 2018 · Primary completion Dec 10, 2019
Drug: Rimegepant; Placebo · For: Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Tucson, Arizona · 93 sites in all
- Safety and Efficacy in Adult Subjects With Acute MigrainesPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03237845 · 1,499 participants · Start Jul 27, 2017 · Primary completion Jan 25, 2018
Drug: Rimegepant; Placebo · For: Migraine, With or Without Aura
Sites: Mobile, Alabama; Glendale, Arizona; Rogers, Arkansas · 50 sites in all
- Safety and Efficacy Study in Adult Subjects With Acute MigrainesPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03235479 · 1,485 participants · Start Jul 18, 2017 · Primary completion Jan 21, 2018
Drug: Rimegepant; Placebo · For: Migraine, With or Without Aura
Sites: Birmingham, Alabama; Gilbert, Arizona; Tempe, Arizona · 50 sites in all
- Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing RegimensPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05217927 · 1,415 participants · Start Mar 4, 2022 · Primary completion Oct 22, 2024
Drug: Rimegepant 75mg daily dosing; Rimegepant 75mg every other day dosing and 1 more · For: Migraine
Sites: Tempe, Arizona; Colton, California; Los Angeles, California · 107 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,108
- nausea1,207
- migraine885
- headache789
- therapeutic product effect incomplete649
- off label use520
- dizziness464
- fatigue463
- vomiting396
- feeling abnormal330
- pain312
- product dose omission issue304
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 8 |
| 2019 | 11 |
| 2020 | 675 |
| 2021 | 1,995 |
| 2022 | 3,581 |
| 2023 | 2,081 |
| 2024 | 1,895 |
| 2025 | 1,715 |
| 2026 | 1,040 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nurtec ODT (Rimegepant Sulfate)
2024 spending
$625M
Beneficiaries
105,323
426,648 claims
Per beneficiary
$5,936
$123.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,933,232 |
| 2021 | $118,402,787 |
| 2022 | $276,493,155 |
| 2023 | $478,240,312 |
| 2024 | $625,230,826 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Croop R, Lipton RB, Kudrow D, et al. · Lancet 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Karlsson WK, Ostinelli EG, Zhuang ZA, et al. · BMJ 2024 · Systematic Review, Comparative Study
- Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
Lipton RB, Croop R, Stock EG, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
Haghdoost F, Puledda F, Garcia-Azorin D, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies.
Dong G, Kjærgaard NA, Shakibfar S, et al. · Expert Opin Drug Saf 2023 · Systematic Review, Meta-Analysis
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Croop R, Goadsby PJ, Stock DA, et al. · Lancet 2019 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.